STOCK TITAN

Global In Vitro Diagnostics Leader bioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Positive)
Tags

bioMérieux, a global leader in in vitro diagnostics, has opened its new Molecular and Genomic Innovation Center at the Navy Yard in Philadelphia. The 32,000 sq. ft. facility houses the xPRO™ Program, which focuses on developing innovative food safety diagnostic solutions. The center includes state-of-the-art labs for genomic discovery and research & development, enabling rapid ideation, development, and validation of new assays.

The expansion is part of bioMérieux's Augmented Diagnostics approach, aiming to redefine diagnostic testing capabilities in food safety. The company celebrated the opening with a $10,000 donation to the Science Center's FirstHand™ program, supporting STEM education for students. The new facility strengthens bioMérieux's presence in Philadelphia's thriving life sciences innovation hub and reinforces its commitment to addressing global food safety challenges.

bioMérieux, leader globale nel campo della diagnostica in vitro, ha aperto il suo nuovo Centro di Innovazione Molecolare e Genomica nel Navy Yard di Philadelphia. La struttura di 32.000 piedi quadrati ospita il Programma xPRO™, che si concentra sullo sviluppo di soluzioni diagnostiche innovative per la sicurezza alimentare. Il centro include laboratori all'avanguardia per la scoperta genomica e la ricerca e sviluppo, consentendo un'ideazione, sviluppo e validazione rapidi di nuovi saggi.

L'espansione fa parte dell'approccio di bioMérieux Diagnostica Aumentata, che mira a ridefinire le capacità di test diagnostici nella sicurezza alimentare. La società ha celebrato l'apertura con una donazione di $10.000 al programma FirstHand™ del Science Center, a sostegno dell'educazione STEM per gli studenti. La nuova struttura rafforza la presenza di bioMérieux nel fiorente polo di innovazione nelle scienze della vita di Philadelphia e riafferma il suo impegno ad affrontare le sfide globali della sicurezza alimentare.

bioMérieux, líder mundial en diagnósticos in vitro, ha inaugurado su nuevo Centro de Innovación Molecular y Genómica en el Navy Yard de Filadelfia. La instalación de 32,000 pies cuadrados alberga el Programa xPRO™, que se centra en desarrollar soluciones diagnósticas innovadoras para la seguridad alimentaria. El centro incluye laboratorios de última generación para el descubrimiento genómico e investigación y desarrollo, lo que permite una rápida ideación, desarrollo y validación de nuevos ensayos.

La expansión es parte del enfoque de bioMérieux Diagnósticos Aumentados, que tiene como objetivo redefinir las capacidades de pruebas diagnósticas en la seguridad alimentaria. La empresa celebró la apertura con una donación de $10,000 al programa FirstHand™ del Science Center, apoyando la educación STEM para los estudiantes. La nueva instalación fortalece la presencia de bioMérieux en el floreciente centro de innovación en ciencias de la vida de Filadelfia y refuerza su compromiso para abordar los desafíos globales de seguridad alimentaria.

bioMérieux체외 진단 분야의 글로벌 리더로서 필라델피아 네이비 야드에 새로운 분자 및 유전체 혁신 센터를 개장했습니다. 32,000 제곱피트의 시설은 혁신적인 식품 안전 진단 솔루션 개발에 중점을 둔 xPRO™ 프로그램을 수용하고 있습니다. 이 센터는 유전체 발견과 연구 및 개발을 위한 최첨단 실험실을 갖추고 있어 새로운 분석 방법의 신속한 구상, 개발 및 검증이 가능합니다.

이번 확장은 식품 안전에서의 진단 능력을 재정의하려는 bioMérieux의 증강 진단 접근 방식의 일환입니다. 회사는 STEM 교육을 지원하는 Science Center의 FirstHand™ 프로그램에 $10,000를 기부하며 개장을 기념했습니다. 이 새로운 시설은 필라델피아의 번창하는 생명 과학 혁신 허브에서 bioMérieux의 존재를 강화하고, 세계적인 식품 안전 문제 해결에 대한 회사의 의지를 더욱 확고히 하고 있습니다.

bioMérieux, leader mondial dans le domaine du diagnostic in vitro, a ouvert son nouveau Centre d'Innovation Moléculaire et Génomique au Navy Yard à Philadelphie. Ce bâtiment de 32 000 pieds carrés abrite le Programme xPRO™, qui se concentre sur le développement de solutions de diagnostic innovantes pour la sécurité alimentaire. Le centre comprend des laboratoires à la pointe de la technologie pour la découverte génomique et la recherche & développement, permettant une idéation, un développement et une validation rapides de nouveaux tests.

Cette expansion fait partie de l'approche Diagnostics Augmentés de bioMérieux, visant à redéfinir les capacités de tests diagnostiques dans la sécurité alimentaire. L'entreprise a célébré l'ouverture avec un don de 10 000 $ au programme FirstHand™ du Science Center, soutenant l'éducation STEM pour les étudiants. Le nouvel établissement renforce la présence de bioMérieux dans le pôle d'innovation florissant en sciences de la vie de Philadelphie et renforce son engagement à relever les défis mondiaux de la sécurité alimentaire.

bioMérieux, ein globaler Marktführer im Bereich der in-vitro-Diagnostik, hat sein neues Molekular- und Genomik-Innovationszentrum im Navy Yard in Philadelphia eröffnet. Die 32.000 Quadratfuß große Einrichtung beherbergt das xPRO™-Programm, das sich auf die Entwicklung innovativer diagnostischer Lösungen für die Lebensmittelsicherheit konzentriert. Das Zentrum umfasst modernste Labore für genomische Entdeckungen sowie Forschung und Entwicklung, die eine schnelle Ideengenerierung, Entwicklung und Validierung neuer Tests ermöglichen.

Die Expansion ist Teil des Augmented Diagnostics-Ansatzes von bioMérieux, der darauf abzielt, die diagnostischen Testmöglichkeiten im Bereich der Lebensmittelsicherheit neu zu definieren. Das Unternehmen feierte die Eröffnung mit einer Spende von 10.000 US-Dollar an das FirstHand™-Programm des Science Centers, das die STEM-Ausbildung für Schüler unterstützt. Die neue Einrichtung stärkt die Präsenz von bioMérieux im florierenden Innovationszentrum der Lebenswissenschaften in Philadelphia und unterstreicht sein Engagement, globale Herausforderungen im Bereich der Lebensmittelsicherheit anzugehen.

Positive
  • None.
Negative
  • None.

bioMérieux's Latest 32,000 sq. ft. Global Food Safety and Quality Site is Home to the xPRO Program that Rapidly Innovates Cutting-Edge Molecular Assays in Partnership with Industry Leaders 

PHILADELPHIA, Sept. 18, 2024 /PRNewswire/ -- bioMérieux, a world leader in in vitro diagnostics, celebrates the opening of the company's Molecular and Genomic Innovation Center. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health. bioMérieux's global leadership team was on-site for the ribbon cutting event, as Philadelphia continues to fortify its reputation as a hotbed of innovation in Life Sciences across North America.

bioMérieux, a world leader in in vitro diagnostics, opens the Molecular and Genomic Innovation Center in Philadelphia

"The opening of the Molecular and Genomic Innovation Center at the Navy Yard is an important milestone in bioMérieux's storied legacy, as we continue to provide game changing diagnostic solutions that solve the food safety industry's most persistent and urgent challenges," said Miguel Villa, Sr. Vice President, Industrial Applications, Americas, and xPRO™ sponsor, "This facility - in conjunction with our unique Augmented Diagnostics approach to food safety - allows us to continue redefining the role and capabilities of diagnostic testing to further ensure public health and fortify brand reputations."

Since 2019, the xPRO Program has continuously developed innovative testing solutions that reduce food and beverage safety pain points across the entirety of the production process, from raw materials to final quality assurance releases. The expansion of bioMérieux at The Navy Yard - which features a team of 50 - is key to maintaining the pace of innovation to meet global customer needs. Increased space for state-of-the-art labs - including The Genomic Discovery Center (investigation and discovery) and The xPRO™ Research & Development Center (assay development, validation and production) - allows for rapid ideation, development and validation, meaning a shorter market launch time for clients.

"The Molecular and Genomic Innovation Center opening marks not just the unveiling of a new building but underscores our commitment to enhancing our operational capabilities and fostering innovation in molecular diagnostics, an integral part of our Augmented Diagnostics approach. With this landmark, we are poised to strengthen our support to our customers in food safety worldwide," said Yasha Mitrotti, EVP Industrial Applications, Microbiology.

In addition to a ribbon cutting ceremony, bioMérieux commemorated the opening with a $10,000 donation to the Science Center's FirstHand™ program, a free, year-round STEM learning program for middle and high school students designed to provide skill-based career exposure. bioMérieux is a longtime partner of the Science Center, providing mentoring and on-site job shadow opportunities for FirstHand students.

"We couldn't be more excited to deepen our roots in Philadelphia, which has long supported our organization through its commitment to fostering an entrepreneurial environment that promotes innovation and collaboration," said Ben Pascal, global head of the xPRO™ Program, "As the innovation leader in the market and with our focus on maintaining a culture of entrepreneurship, the new site bolsters our ability to rapidly respond and develop breakthrough innovations that change the paradigm for global food safety."

bioMérieux selected to open the site at the Navy Yard, which serves the region as an innovation Life Sciences hub focused on research and development, commercialization and manufacturing, and boasts a roster of regional and global companies currently occupying more than one-million square feet of life sciences and advanced manufacturing space. The opening of bioMérieux at the Navy Yard strengthens the sites reputation as a foremost innovation hub across the US.

Part of bioMérieux's Augmented Diagnostics approach, the xPRO™ Program is the catalyst advancing molecular diagnostics, solving the food industry's complex food safety operational challenges through direct partnership to diagnose the root cause of food safety obstacles and develop innovative, custom testing solutions to ensure public safety while minimizing waste and maximizing efficiency. The trusted partner in Augmented Diagnostics for clients including Body Armor, Victory Brewing Company, Jackson Family Wines, Herbalife and more, bioMérieux's xPRO™ Program is open to food, beverage, dietary supplement and cannabis companies of any size that are looking to improve their quality assurance and diagnostic testing services. For more information on the xPRO™ Program, please visit go.biomerieux.com/xPRO. 

ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
www.biomerieux.com.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP 

ABOUT FIRSTHAND
The Science Center's nationally recognized FirstHand™ program has provided free year-round STEM learning for over 2,500 middle and high school students in Philadelphia since it launched in 2014. The industry-informed curricula offer skills-based career exposure, giving students real-world, hands-on experience across a vast array of STEM fields.

Established in 1963, the Science Center has been Philadelphia's premier catalyst for entrepreneurial activity, life sciences innovation, and economic growth for over 60 years. Recognized by The Brookings Institution as a leading investor, mentor, and economic development partner, the nonprofit supports early-stage companies that together contribute $7.8 billion annually to the Greater Philadelphia economy.

CONTACTS
MEDIA RELATIONS
Maggie DiSantis
+1 (331) 385-1332
maggie.disantis@biomerieux.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/global-in-vitro-diagnostics-leader-biomerieux-celebrates-the-opening-of-the-molecular-and-genomic-innovation-center-at-the-navy-yard-in-philadelphia-302252193.html

SOURCE bioMérieux

FAQ

What is the purpose of bioMérieux's new Molecular and Genomic Innovation Center in Philadelphia?

The new center houses the xPRO™ Program, which develops innovative food safety diagnostic solutions. It includes state-of-the-art labs for genomic discovery and research & development, enabling rapid ideation, development, and validation of new assays to address food safety challenges.

How large is bioMérieux's new facility at the Navy Yard in Philadelphia?

The new Molecular and Genomic Innovation Center is a 32,000 sq. ft. facility located at the Navy Yard in Philadelphia.

What is the xPRO™ Program mentioned in the bioMérieux (BMXXY) press release?

The xPRO™ Program is bioMérieux's initiative that partners with industry leaders to develop innovative testing solutions for food and beverage safety. It aims to streamline operational efficiencies and address unmet needs in the food safety industry.

How does bioMérieux's new center in Philadelphia contribute to food safety?

The center enables bioMérieux to rapidly develop and validate cutting-edge molecular assays for food safety diagnostics. It supports the company's Augmented Diagnostics approach, which aims to redefine diagnostic testing capabilities and ensure public health in the food industry.

What donation did bioMérieux make to commemorate the opening of its new center in Philadelphia?

bioMérieux made a $10,000 donation to the Science Center's FirstHand™ program, which provides free, year-round STEM learning opportunities for middle and high school students.

BIOMERIEUX S A UNSP/ADR

OTC:BMXXY

BMXXY Rankings

BMXXY Latest News

BMXXY Stock Data

11.62B
36.57M
Diagnostics & Research
Healthcare
Link
United States of America
Marcy-l'Étoile